TCI Peptide Therapeutics was formed in 2009 to create best in class peptide drug candidates with better safety and efficacy properties than other drugs in the same class. TCI's lead drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions. It is currently being used in a canine trial recruiting nationwide. Included in our drug development programs is a licensed Angiotensin (1-7) anti-tumor agent and discovery stage programs for antimicrobial, anti-biofilm and antiviral peptides.
View Top Employees from TCI Peptide Therapeutics| Website | http://endevicabio.com |
| Employees | 5 (5 on RocketReach) |
| Founded | 2009 |
| Address | 1601 S Providence Rd, Columbia, Missouri 65211, US |
| Phone | (573) 881-5080 |
| Industry | Biotechnology, Drug Discovery, Pharmaceuticals, Healthcare |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541713 Companies |
Looking for a particular TCI Peptide Therapeutics employee's phone or email?
TCI Peptide Therapeutics Questions
Leann Kuhlmann is the Vice President of Clinical Development of TCI Peptide Therapeutics.
5 people are employed at TCI Peptide Therapeutics.
TCI Peptide Therapeutics is based in Columbia, Missouri.
The NAICS codes for TCI Peptide Therapeutics are [541, 54171, 54, 5417, 541713].
The SIC codes for TCI Peptide Therapeutics are [873, 87].
Top TCI Peptide Therapeutics Employees
-
33
-
View
Leann Kuhlmann
Vice President of Clinical Development at TCI Peptide Therapeutics
Grand Rapids, MI, US11 -
31
